Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Jingjing WeiShanshan LiuXinlu WangBin LiLijie QiaoYongxia WangMing-Jun ZhuPublished in: Evidence-based complementary and alternative medicine : eCAM (2021)
SBP could demonstrate a beneficial role in patients with CHD after PCI of reducing the incidence of MACE and improving LVEF, NT-pro-BNP, inflammatory mediators, and blood lipid index. However, limited by the quantity and quality of eligible studies, the above conclusions required more standardized, rigorous, high-quality clinical trials to verify further.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- clinical trial
- acute coronary syndrome
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- antiplatelet therapy
- coronary artery bypass grafting
- atrial fibrillation
- risk factors
- oxidative stress
- coronary artery bypass
- phase ii
- fatty acid
- anti inflammatory
- heart failure
- left ventricular
- study protocol